About Aroa Biosurgery
Aroa Biosurgery is a publicly listed company based in Mangere (New Zealand) founded in 2008. It operates as a developer of medical and surgical products for soft tissue reconstruction. Its website aroa.com draws about 11 thousand monthly visits. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its competitors include Humacyte, Kerecis, Miach Orthopaedics, CUTISS and Rotation Medical and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Aroa Biosurgery was founded in 2008 in Mangere, New Zealand, and operates in the medical and surgical sector. Proprietary AROA ECM technology is utilized to create extracellular matrix biomaterials derived from ovine forestomach. These materials support wound healing and soft tissue reconstruction. Key products include Endoform, Myriad Matrix, Myriad Morcells, and Reinforced Bioscaffold, which are applied in clinical settings for tissue repair.
- Annual Revenue$63.56 M (USD)19.7as on Mar 31, 2026
- Net Profit$2.87 M (USD)0as on Mar 31, 2026
- EBITDA$6.22 M (USD)953.36as on Mar 31, 2026
People of Aroa Biosurgery
2 people are tracked at Aroa Biosurgery (2 in leadership).
| Name | Role | Group |
|---|---|---|
Steve Barnard Engle | – | Leadership |
John Richard Pinion Ii | – | Leadership |
Complete people profiles for Aroa Biosurgery
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aroa Biosurgery
Aroa Biosurgery is a publicly listed company on the ASX with ticker symbol ARX in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jul 2020
- Listed onASX: ARX
- Listed entityAROA BIOSURGERY LIMITED
- Exchange sectorHealth technology
- ISINNZARXE0001S1
- Share price0.53 AUD (+5% on the day) · 2026-10-14
- Market capitalisation172,951,324.00 AUD
- Price to earnings48.2
- EPS (diluted, trailing year)0.01 AUD
- Volume (last session)92,107
Financials of Aroa Biosurgery
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 92.3M AUD | 4.2M AUD | 9.0M AUD |
| 2024 | 77.1M AUD | -3.5M AUD | 857,500 AUD |
| 2023 | 64.0M AUD | -9.8M AUD | -7.4M AUD |
| 2022 | 57.7M AUD | -360,830 AUD | -915,750 AUD |
| 2021 | 37.4M AUD | -7.9M AUD | -5.3M AUD |
Detailed financial statements for Aroa Biosurgery
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Aroa Biosurgery
Aroa Biosurgery has 9 listed competitors in our database, 9 of them funded. They include Humacyte, Kerecis, Miach Orthopaedics, CUTISS and Rotation Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humacyte.com | 2004 | Morrisville, United States | $424.76M | 70 | Human tissue-based products are developed for vascular disease applications. | |
| kerecis.com | 2007 | Isafjordur, Iceland | $93.11M | 150 | Fish-skin acellular dermal matrix technology is provided for wound treatments. | |
| miachortho.com | 2016 | Boston, United States | $72.5M | – | Bio-engineered surgical implants for connective tissue repair are developed. | |
| cutiss.swiss | 2017 | Zurich, Switzerland | $94.37M | – | Personalized skin tissue therapy is developed by CUTISS for surgeries. | |
| rotationmedical.com | 2009 | Minneapolis, United States | $54.58M | 34 | A rotator cuff repair system is developed for disease treatment. | |
| cayennemedical.com | 2005 | Phoenix, United States | $46.3M | 54 | Soft tissue reconstruction solutions for knee and shoulder | |
| kitotechmedical.com | 2011 | Seattle, United States | $20.85M | – | Developer of a device to close wounds, lacerations, and surgical incisions | |
| micromendskinclosure.com | 2017 | Seattle, United States | $3.41M | – | Solutions for treating dermatological disorders are provided by microMend. | |
| solsysmedical.com | 1999 | Norfolk, United States | $29.55M | – | Human skin allografts and dressings for wound care are supplied. |
Detailed competitors of Aroa Biosurgery
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aroa Biosurgery
The website of Aroa Biosurgery (aroa.com) receives about 10.9K visits a month.
- Monthly visits10.9K
▲ 3.9% vs previous month
Top companies in Orthopedics
10 companies that operate in the same segment as Aroa Biosurgery (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | 4,125 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608.25 M | – | 197 | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aroa Biosurgery
Complete news archive for Aroa Biosurgery
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aroa Biosurgery
Aroa Biosurgery was founded in 2008.
Aroa Biosurgery is headquartered in Mangere, New Zealand.
Annual revenue of Aroa Biosurgery is $63.56M as on Mar 31, 2026.
Aroa Biosurgery was founded in 2008 in Mangere, New Zealand, and operates in the medical and surgical sector. Proprietary AROA ECM technology is utilized to create extracellular matrix biomaterials derived from ovine forestomach. These materials support wound healing and soft tissue reconstruction. Key products include Endoform, Myriad Matrix, Myriad Morcells, and Reinforced Bioscaffold, which are applied in clinical settings for tissue repair.
Yes, Aroa Biosurgery is publicly traded on ASX under the ticker symbol ARX.